Stocks
Merck KGaA Boosts 2026 Earnings Forecast Amid Strong Demand
Merck KGaA has raised its earnings forecast for 2026, expecting between €5.9 billion and €6.3 billion in adjusted EBITDA. This is an increase from its previous range of €5.7 billion to €6.1 billion.
The German company posted better-than-expected quarterly results, with a 9.4% year-over-year increase in adjusted EBITDA to €1.60 billion.
This success can be attributed to strong demand for Merck's drug manufacturing supplies and semiconductor materials.
The company has also made significant moves in its Life Science unit, including the $11.3 billion acquisition of Bio-Techne in June.